BioCryst Pharmaceuticals (NASDAQ:BCRX): Q2 EPS of -$0.23 beats by $0.02. Revenue of $4.8M (+80%)...

Jul. 30, 2009 7:31 AM ETBioCryst Pharmaceuticals, Inc. (BCRX)BCRXBy: Eli Hoffmann, SA News Editor

BioCryst Pharmaceuticals (NASDAQ:BCRX): Q2 EPS of -$0.23 beats by $0.02. Revenue of $4.8M (+80%) vs. $4.1M. R&D expenses decreased to $11.2M from $13.4M a year ago. (PR)

Recommended For You

Comments

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.